Optimer Pharma (OPTR) Said to Draw Interest from Glaxo (GSK), Astellas
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Many senior Amazon employees won't get cash raises this year - Fortune
Cantor Fitzgerald Downgrades Cubist Pharmaceuticals (CBST) to Sell; Doesn't See Deal for Optimer (OPTR)
April 3, 2013 7:48 AM EDTCantor Fitzgerald downgraded Cubist Pharmaceuticals (NASDAQ: CBST) from Hold to Sell but raised its price target from $38 to $40 saying an Optimer (NASDAQ: OPTR) deal is unlikely.
Analyst Adeyemi Ogunkoya notes that Cubist traded up in tandem with Optimer after the company announced on Feb... More